NucleicAI

Sinclair Dokos is a commercial and technology leader who scaled Oxford Nanopore Technologies. She joins a leadership team that includes co-founders and Harvard professors Alireza Haghighi and David A. Sinclair.

The signing of the Memorandum of Understanding took place at the IEEE International Conference on AI × Medicine, Health, and Care in Taichung, featuring a keynote by Prof. Alireza Haghighi and remarks by Asia University President, Prof. Jeffrey J.P. Tsai.

"This partnership with NucleicAI represents a significant step toward building the next-generation health data ecosystem. By integrating global technology with local excellence, we're accelerating discovery in alignment with Asia University's strategic vision to lead in biomedical innovation."

"Taiwan's biomedical and academic ecosystem is uniquely positioned to lead the next wave of health innovation. This collaboration builds a comprehensive data infrastructure to accelerate predictive, preventive, and precision medicine, while enabling novel drug discovery."

"This is the kind of ambitious, forward-thinking collaboration that transforms how we use data to advance human health and longevity. We are thrilled to partner with leading institutions in Taiwan to demonstrate what's possible when AI meets life science at scale."

This collaboration also includes research in genomics, AI-driven analytics, and human longevity while emphasizing data sovereignty and best practices in data governance.

Asia University will migrate its life science and healthcare data to the platform, enabling robust collaboration, privacy-preserving analytics, AI-powered insights, and broader global partnerships, particularly with leading industry stakeholders. It will also collaborate with other top institutions across Taiwan to support the secure migration of their data, further strengthening national collaboration and driving innovation.

Voet will lead the design and integration of NucleicAI's advanced genomics and health intelligence infrastructure, scaling its capabilities in secure, high-throughput data processing and multimodal machine learning and AI.

At the Broad Institute, Voet spent more than a decade developing large-scale computational pipelines and genomic analysis frameworks that have become foundational tools for global biomedical research. His expertise spans distributed systems, genomic data integration, and scalable AI architectures, all core components of NucleicAI's mission.

"Douglas brings world-class experience in software platform architecture and computational genomics. His leadership in building reliable, scalable systems will be instrumental as we expand NucleicAI's platform globally to support national-scale precision medicine and longevity research initiatives."

"We are thrilled to welcome Douglas to the NucleicAI team. His ability to translate complex biological data into actionable intelligence aligns perfectly with our vision to revolutionize human longevity through AI-driven data analysis."

"I'm excited to join NucleicAI at such a pivotal moment. The company's commitment to building a global health intelligence platform anchored in scientific rigor, data integrity, and AI innovation resonates deeply with me. I look forward to leading the team that makes this vision possible."

NucleicAI continues to build a team of scientists, engineers, and clinicians dedicated to reimagining how biological data is collected, analyzed, and applied to human longevity. The company's platform is designed to power national-scale genomics and longevity programs, integrating AI with multiomic data to enable predictive, preventive, and personalized medicine.